journal article·2026-01Open access

Steap4 Promotes Senile Osteoporosis via Fe 2+ ‐ROS/C/EBPβ Feedback‐Driven Ferroptosis and Adipogenesis in Senescent BMSCs

Liangliang Wang, Guangrong Yin, Wenming Li, Maoyuan Li, Feng Lu, Chao Xu, Gongyin Zhao, Dechun Geng, Jiaxiang Bai, Yuji Wang

Advanced Science· Volume 13· Issue 5

Abstract

Abstract Senile osteoporosis (SOP) is a systemic bone disease characterized by increased susceptibility to fractures. In this study, it is found that senescent bone marrow mesenchymal stem cells (BMSCs) exhibit increased sensitivity to ferroptosis, a phenomenon associated with Steap4, a nicotinamide adenine dinucleotide phosphate hydrogen (NADPH)‐dependent metalloreductase that reduces Fe 3+ to Fe 2+ . Therefore, it is aimed to innovatively elucidate how Steap4 affects ferroptosis in senescent BMSCs. These findings indicate that Steap4 promotes intracellular Fe 2+ accumulation and elevates reactive oxygen species (ROS) levels, collectively driving the upregulation of CCAAT/enhancer binding protein beta (C/EBPβ) expression. Interestingly, a functional C/EBPβ binding site is identified within the Steap4 promoter region. Mechanistically, knockdown studies demonstrated that C/EBPβ depletion attenuated Steap4 expression, whereas C/EBPβ overexpression conversely upregulated Steap4 levels. These regulatory processes establish a self‐amplifying Steap4/Fe 2+ ‐ROS/C/EBPβ positive feedback loop. Notably, a large number of adipocytes are also observed in the bone marrow of aged mice. Knockdown of Steap4 and C/EBPβ suppressed the differentiation of BMSCs into adipocytes. Knockdown of Steap4 or deferoxamine (DFO) treatment in animal experiments effectively relieves SOP. In conclusion, Steap4 accelerates the onset of ferroptosis in senescent BMSCs and promotes their differentiation to adipocytes through the Steap4/Fe 2+ ‐ROS/C/EBPβ axis, ultimately impairing their osteogenic capacity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Bone Metabolism and Diseases · TGF-β signaling in diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopaedics the Second People's Hospital of Changzhou the Third Affiliated Hospital of Nanjing Medical University Changzhou Medical Center Nanjing Medical University Changzhou 213003 China

Department of Orthopaedics The First Affiliated Hospital of Soochow University Suzhou 215006 China

Department of Orthopedics Centre for Leading Medicine and Advanced Technologies of IHM The First Affiliated Hospital of USTC Division of Life Sciences and Medicine University of Science and Technology of China Hefei 230001 China

Department of Orthopedic Surgery and Biochemistry and Molecular Biology Mayo Clinic Rochester MN 55902 USA

Funding

National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province · China Postdoctoral Science Foundation

References (37)

Show source-provided references
1. 10.1016/S0140-6736(21)02646-510.1016/S0140-6736(21)02646-5 ↗
2. 10.1002/ctm2.74610.1002/ctm2.746 ↗
3. 10.1038/s41413-023-00247-y10.1038/s41413-023-00247-y ↗
4. 10.1016/j.cell.2022.06.00310.1016/j.cell.2022.06.003 ↗
5. 10.1016/j.diff.2024.10075710.1016/j.diff.2024.100757 ↗
6. 10.1016/j.phymed.2023.15527510.1016/j.phymed.2023.155275 ↗
7. Zhang W. · Chin. J. Orthop. · 2014 · 34 · 39
8. 10.3109/07435800.2016.115560010.3109/07435800.2016.1155600 ↗
9. 10.1002/jbmr.169210.1002/jbmr.1692 ↗
10. 10.3390/cancers1416403410.3390/cancers14164034 ↗
11. 10.1016/j.cellsig.2023.11093310.1016/j.cellsig.2023.110933 ↗
12. 10.1158/1541-7786.MCR-11-028110.1158/1541-7786.MCR-11-0281 ↗
13. 10.1089/ten.tea.2008.051910.1089/ten.tea.2008.0519 ↗
14. 10.1074/jbc.M113.47875010.1074/jbc.M113.478750 ↗
15. 10.1016/j.jbc.2023.10546310.1016/j.jbc.2023.105463 ↗
16. 10.1080/15548627.2023.220055410.1080/15548627.2023.2200554 ↗
17. 10.1038/s41581-023-00689-x10.1038/s41581-023-00689-x ↗
18. 10.1016/j.jacbts.2023.10.00910.1016/j.jacbts.2023.10.009 ↗
19. 10.1016/j.bone.2019.03.04110.1016/j.bone.2019.03.041 ↗
20. 10.1016/j.tig.2019.11.00510.1016/j.tig.2019.11.005 ↗
21. 10.1146/annurev-biochem-052110-11571810.1146/annurev-biochem-052110-115718 ↗
22. 10.1016/j.isci.2022.10454410.1016/j.isci.2022.104544 ↗
23. 10.1111/j.1745-7254.2008.00793.x10.1111/j.1745-7254.2008.00793.x ↗
24. 10.1111/cpr.1332310.1111/cpr.13323 ↗
25. 10.3390/ijms2101034910.3390/ijms21010349 ↗
26. 10.1016/j.freeradbiomed.2023.01.02610.1016/j.freeradbiomed.2023.01.026 ↗
27. 10.1530/JOE-16-059410.1530/JOE-16-0594 ↗
28. 10.1016/j.redox.2020.10157810.1016/j.redox.2020.101578 ↗
29. 10.1038/s41467-022-32435-510.1038/s41467-022-32435-5 ↗
30. 10.7554/eLife.8546410.7554/eLife.85464 ↗
31. 10.1016/j.arr.2024.10223510.1016/j.arr.2024.102235 ↗
32. 10.1038/s41419-023-06317-710.1038/s41419-023-06317-7 ↗
33. 10.2147/IJN.S49471010.2147/IJN.S494710 ↗
34. 10.1016/j.jconrel.2019.07.00910.1016/j.jconrel.2019.07.009 ↗
35. 10.15252/emmm.20221652510.15252/emmm.202216525 ↗
36. 10.1002/advs.20220267910.1002/advs.202202679 ↗
37. 10.1186/s13287-023-03371-y10.1186/s13287-023-03371-y ↗